Special Reports
In-depth commissioned reports on the most clinically and commercially significant topics in life science. Built for biopharma professionals, clinicians, CROs, and investors.
Published Reports
Coming Next
GLP-1 and Beyond: The Oral Revolution in Obesity Medicine
How oral semaglutide and new dual agonists are reshaping the largest therapy area in pharma
Cracking the Undruggable: KRAS Inhibitors Rewrite Solid Tumor Oncology
From G12C to pan-RAS: the mutation-by-mutation guide to the KRAS revolution
MASH 2026: Building on the First-Ever Approved Therapy
Resmetirom changed everything. Now the race is on for combination therapies and broader eligibility
EGFR-Mutated Lung Cancer: A New Survival Benchmark
Amivantamab plus lazertinib vs osimertinib: a survival benchmark four years in the making
HFpEF Finally Has Answers: Finerenone, SGLT2s, and What Comes Next
The largest unmet need in cardiology finally has a multi-drug evidence base
Multiple Myeloma: On the Threshold of Cure
Four bispecific antibodies, two CAR-T therapies, and a treatment landscape that moves monthly
Antibody-Drug Conjugates: The Platform That Ate Oncology
From 1 approval to 15: how the ADC platform reshaped every solid tumor type
Prostate Cancer in the Radioligand Era: Pluvicto Expands
Label expansion triples the eligible population and the infrastructure race begins
Alzheimer Disease-Modifying Therapy: From Approval to Real-World Practice
Lecanemab and donanemab are approved. The harder question is who gets them and how
Autoimmune Disease 2026: JAK Inhibitors Expand, EULAR Rewrites the Playbook
12 FDA-approved JAK inhibitors, updated EULAR guidelines, and the TYK2 era beginning
Pancreatic Cancer Inflection Point: KRAS Moves, Immunotherapy Catches Up
The most resistant cancer is finally responding, and the pipeline is accelerating
CRISPR and Gene Therapy: From Approval to Access
The first CRISPR medicine is approved. Only 64 patients received it all year. Why?
Diffuse Large B-Cell Lymphoma: Frontline Immunotherapy Arrives
R-CHOP has been standard of care for 20 years. frontMIND may be the beginning of the end
Oral PCSK9 Inhibitors: Opening Cardiovascular Prevention to Millions
If approved, an oral PCSK9 inhibitor could reach 10x more patients than injectables ever did
GI Cancers Surge: Targeted Therapy Comes to CRC, Gastric, and Biliary Tract
ASCO 2026 was the year GI oncology arrived: four tumor types, simultaneous breakthroughs
Radioligand Therapy as a Platform: Beyond PSMA to SSTR, FAPI, and Solid Tumors
Novartis proved the concept. Now 20 companies are building the infrastructure
Orexin Agonists: A 20-Year Gap Closes for Narcolepsy
The first therapy to restore orexin signaling, not just manage symptoms, is in Phase 3
Cardio-Renal-Metabolic Syndrome: How a New Diagnosis Changes Everything
The AHA renamed the disease. Now every cardiologist, nephrologist, and endocrinologist must collaborate
Bispecific Antibodies Beyond Hematology: Solid Tumors Enter the Arena
After conquering blood cancers, bispecifics are now targeting lung, breast, and colorectal cancer